Cargando…

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach

Detalles Bibliográficos
Autor principal:	Nisar, Muhammad K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Research and Education Association 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459333/ https://www.ncbi.nlm.nih.gov/pubmed/30071939 http://dx.doi.org/10.5152/eurjrheum.2018.17188

Ejemplares similares

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
por: Purmonen, Timo, et al.
Publicado: (2018)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Successful treatment of refractory folliculitis decalvans with apremilast
por: Fässler, Mirjam, et al.
Publicado: (2020)

Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast
por: Agud‐Dios, Manuel, et al.
Publicado: (2022)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Refractory erythema annulare centrifugum treated with apremilast
por: Lee, Michelle S., et al.
Publicado: (2021)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis
por: Krueger, James G., et al.
Publicado: (2021)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Apremilast induced tinnitus: An unreported side effect
por: Sule, Rajiv Ramesh, et al.
Publicado: (2021)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Apremilast in Refractory Alopecia Areata
por: Estébanez, Andrea, et al.
Publicado: (2019)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

Refractory necrotizing scleritis successfully treated with adalimumab
por: Lawuyi, Lola E., et al.
Publicado: (2016)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Mental health, insomnia and suicidal ideation during treatment with apremilast
por: Cowan, Timothy L., et al.
Publicado: (2022)

Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
por: De, Abhishek, et al.
Publicado: (2019)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series
por: Ständer, Sascha, et al.
Publicado: (2020)

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
por: Ikumi, Kyoko, et al.
Publicado: (2021)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
por: Agusti-Mejias, Anna, et al.
Publicado: (2013)

Refractory Myasthenia Gravis Treated Successfully with Rituximab: A Case Report
por: Rahul, L Yadav, et al.
Publicado: (2017)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Excellent Response to Secukinumab in Treatment Resistant Impetigo Herpetiformis
por: Neema, Shekhar, et al.
Publicado: (2022)

Commentary: Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series
por: Hackley, Madison, et al.
Publicado: (2023)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f3qgr777pm8v7b5b00aqhah8uh